Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mayne Pharma Group ( (AU:MYX) ) just unveiled an announcement.
Mayne Pharma Group Limited has issued 1,356,532 new fully paid ordinary shares following the exercise or conversion of previously unquoted options or other convertible securities, with an effective issue date of 22 December 2025. The move modestly increases the company’s share capital base and reflects the crystallisation of equity-based incentives or financing instruments, which may slightly dilute existing shareholders while signalling ongoing engagement of option and convertible security holders with the company’s equity.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited, listed on the ASX under the code MYX, operates in the pharmaceutical industry, focusing on the development, manufacture and commercialisation of specialty and generic medicines for global markets.
Average Trading Volume: 563,933
Technical Sentiment Signal: Sell
Current Market Cap: A$253.5M
See more insights into MYX stock on TipRanks’ Stock Analysis page.